Other Medtronic CRT Devices
 

Other Medtronic CRT Devices

Cardiac resynchronization therapy (CRT) is a proven treatment for selected patients with heart failure-induced conduction disturbances and ventricular dyssynchrony. When used in combination with stable, optimal medical therapy, CRT is designed to reduce symptoms and improve cardiac function by restoring the mechanical sequence of ventricular activation and contraction.

Consulta CRT-D Device

Consulta CRT-D

Consulta CRT-D Device

A high-energy, wireless device with features that help to ensure CRT.

Key features include:

Important Safety Information

For CRT-D devices, certain programming and device operations may not provide cardiac resynchronization. Changes in a patient's disease and/or medications may alter the efficacy of a device's programmed parameters.

Specifications 

Volume 38 cc
Size (H x W x D) 69 x 51 x 15 mm
Mass 68 g

References

  1. Yu CM, Wang L, Chau E, et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. August 9,2005;112(6):841-848.
  2. Vollmann D, Nägele H, Schauert P, et al. Clinical utility of intrathoracic impedance monitoring to alert patients with an implanted device of deteriorating chronic heart failure. Eur Heart J. August 2007;28(15):1835-1840.
  3. Catanzariti D, Lunati M, Landolina M, et al. Monitoring intrathoracic impedance with an implantable defibrillator reduces hospitalizations in patients with heart failure. PACE. March 2008;32(3):363-370.
  4. Perego GB, Landolina M, Vergara G, et al. Implantable CRT device diagnostics identify patients with increased risk for heart failure hospitalization. J Interv Card Electrophysiol. December 2008;23(3):235-242.
  5. Small RS, Wickemeyer W, Germany R, et al. Changes in intrathoracic impedance are associated with subsequent risk of hospitalizations for acute decompensated heart failure: clinical utility of implanted device monitoring without a patient alert. J Card Fail. August 2009;15(6):475-481.
  6. Abraham WT. Superior performance of intrathoracic impedance-derived fluid index versus daily weight monitoring in heart failure patients. Results of the Fluid Accumulation Status Trial. Late Breaking Clinical Trials. J Card Fail. Vol.15 No. 9 2009, p 813.
  7. Whellan DJ, Ousdigian KT, Al-Khatib SM, et al. Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients with Heart Failure) study. J Am Coll Cardiol. April 27, 2010;55(17):1803-1810.

Concerto II CRT-D

other-hcp_crt-concerto2

Concerto II CRT-D Device

A high-energy, wireless device with features that help to ensure CRT.

Key features include:

Important Safety Information

Changes in patient's disease and/or medications may alter the efficacy of a device's programmed parameters or related features.

Specifications
Volume 38 cc
Size (H x W x D) 69 x 51 x 15 mm
Mass 68 g

References

  1. Yu CM, Wang L, Chau E, et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. August 9,2005;112(6):841-848.
  2. Vollmann D, Nägele H, Schauert P, et al. Clinical utility of intrathoracic impedance monitoring to alert patients with an implanted device of deteriorating chronic heart failure. Eur Heart J. August 2007;28(15):1835-1840.
  3. Catanzariti D, Lunati M, Landolina M, et al. Monitoring intrathoracic impedance with an implantable defibrillator reduces hospitalizations in patients with heart failure. PACE. March 2008;32(3):363-370.
  4. Perego GB, Landolina M, Vergara G, et al. Implantable CRT device diagnostics identify patients with increased risk for heart failure hospitalization. J Interv Card Electrophysiol. December 2008;23(3):235-242.
  5. Small RS, Wickemeyer W, Germany R, et al. Changes in intrathoracic impedance are associated with subsequent risk of hospitalizations for acute decompensated heart failure: clinical utility of implanted device monitoring without a patient alert. J Card Fail. August 2009;15(6):475-481.
  6. Abraham WT. Superior performance of intrathoracic impedance-derived fluid index versus daily weight monitoring in heart failure patients. Results of the Fluid Accumulation Status Trial. Late Breaking Clinical Trials. J Card Fail. Vol. 15 No. 9 2009, p 813.
  7. Whellan DJ, Ousdigian KT, Al-Khatib SM, et al. Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients with Heart Failure) study. J Am Coll Cardiol. April 27, 2010;55(17):1803-1810.

Maximo II CRT-D

other-hcp_crt-maximo2

Maximo II CRT-D Device

A high-energy, wireless device with proven shock reduction and features that help to ensure CRT.

Key features include:

Important Safety Information

Changes in patient's disease and/or medications may alter the efficacy of a device's programmed parameters or related features.

Specifications
Volume38 cc
Size (H x W x D69 x 51 x 15 mm
Mass68 g
Pace/sense portsThree IS-1 bipolar (A, RV, LV)
Defibrillation portsTwo DF-1 (RV coil [HVB], SVC [HVX]
External shieldTitanium
Radiopaque IDPUG
BatteryLithium silver vanadium oxide

References

  1. Wathen MS, DeGroot PJ, Sweeney MO, et al, for the PainFREE Rx II Investigators. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation. October 26, 2004;110(17):2591-2596.

 

InSync Sentry CRT-D Device

other-hcp_crt-insyncs

InSync Sentry CRT-D Device

The world’s first device with OptiVol Fluid Status Monitoring provides proven cardiac resynchronization and ICD therapies.

Key features include:

Important Safety Information

Changes in a patient’s disease and/or medications may alter the efficacy of a device’s programmed parameters or related features.

Specifications
Volume 40 cc
Size (H x W x D 73 x 51 x 15 mm
Mass 78 g
 

References

  1. Yu CM, Wang L, Chau E, et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. August 9,2005;112(6):841-848.
  2. Vollmann D, Nägele H, Schauert P, et al. Clinical utility of intrathoracic impedance monitoring to alert patients with an implanted device of deteriorating chronic heart failure. Eur Heart J. August 2007;28(15):1835-1840.
  3. Catanzariti D, Lunati M, Landolina M, et al. Monitoring intrathoracic impedance with an implantable defibrillator reduces hospitalizations in patients with heart failure. PACE. March 2008;32(3):363-370.
  4. Perego GB, Landolina M, Vergara G, et al. Implantable CRT device diagnostics identify patients with increased risk for heart failure hospitalization. J Interv Card Electrophysiol. December 2008;23(3):235-242.
  5. Small RS, Wickemeyer W, Germany R, et al. Changes in intrathoracic impedance are associated with subsequent risk of hospitalizations for acute decompensated heart failure: clinical utility of implanted device monitoring without a patient alert. J Card Fail. August 2009;15(6):475-481.
  6. Abraham WT. Superior performance of intrathoracic impedance-derived fluid index versus daily weight monitoring in heart failure patients. Results of the Fluid Accumulation Status Trial. Late Breaking Clinical Trials. J Card Fail. Vol. 15 No. 9 2009, p 813.
  7. Whellan DJ, Ousdigian KT, Al-Khatib SM, et al. Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients with Heart Failure) study. J Am Coll Cardiol. April 27, 2010;55(17):1803-1810.
 

InSync II Marquis CRT-D Device

other-hcp_crt-insync2

InSync II Marquis CRT-D Device

Patient-tailored CRT options for heart failure management along with ICD protection.

Key features include:

  • Painless anti-tachycardia pacing (ATP) therapy that terminates 3 out of 4 episodes of fast ventricular tachycardia1
  • Sophisticated device diagnostics for help in assessing a patient’s clinical status
  • Remote device follow-up with the exclusive Medtronic CareLink® Network

Important Safety Information

Changes in a patient’s disease and/or medications may alter the efficacy of a device’s programmed parameters or related features.

Mechanical Specifications

Volume 38 cc
Size (H x W x D 73 x 51 x 14 mm
Mass 77 g

References

  1. Wathen MS, Sweeney MO, DeGroot PJ, et al. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation. August 14, 2001;104:796-801.
Last updated: 26 Feb 2013

Related Therapy

Heart Failure Management

Medtronic Fully Integrated CRT Implant System

Medtronic 24-hour Technical Support

(800) 328-2518